Exelixis Inc. (NASDAQ:EXEL) shares traded 1.02% higher at $19.89 on Wall Street last session.
In accordance with the data, 16 analysts cover Exelixis Inc. (NASDAQ:EXEL). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $17.00, we find $25.00. Given the previous closing price of $19.69, this indicates a potential upside of 26.97 percent. EXEL stock price is now 3.06% away from the 50-day moving average and 11.84% away from the 200-day moving average. The market capitalization of the company currently stands at $6.54B.
It has been rated a hold by 2 analysts and a buy by 12. Brokers who have rated the stock have averaged $24.93 as their price target over the next twelve months.
In other news, Hessekiel Jeffrey, EVP, General Counsel & Sec sold 38,930 shares of the company’s stock on Apr 05. The stock was sold for $778,989 at an average price of $20.01. Upon completion of the transaction, the EVP, General Counsel & Sec now directly owns 582,435 shares in the company, valued at $11.58 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 10, Director WYSZOMIERSKI JACK L sold 15,300 shares of the business’s stock. A total of $254,133 was realized by selling the stock at an average price of $16.61. This leaves the insider owning 317,467 shares of the company worth $6.31 million. Insiders disposed of 1,015,882 shares of company stock worth roughly $20.21 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EXEL stock. A new stake in Exelixis Inc. shares was purchased by DEEP TRACK CAPITAL, LP during the first quarter worth $38,425,000. BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC invested $35,557,000 in shares of EXEL during the first quarter. In the first quarter, CALIGAN PARTNERS LP acquired a new stake in Exelixis Inc. valued at approximately $16,907,000. SOFINNOVA INVESTMENTS, INC. acquired a new stake in EXEL for approximately $16,533,000. TEKLA CAPITAL MANAGEMENT LLC purchased a new stake in EXEL valued at around $14,453,000 in the second quarter. In total, there are 548 active investors with 88.10% ownership of the company’s stock.
During the past 12 months, Exelixis Inc. has had a low of $14.87 and a high of $22.04. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 5.00, and a quick ratio of 4.90. According to the stock market information, the enterprise value for the company is $5.35B, which is based on a 42.14 price-to-earnings ratio, a 1.55 price-to-earnings-growth ratio, and a beta of 0.67. The fifty day moving average price for EXEL is $19.31 and a two-hundred day moving average price translates $17.80 for the stock.
The latest earnings results from Exelixis Inc. (NASDAQ: EXEL) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.12, missing analysts’ expectations of $0.15 by -0.03. This compares to $0.21 EPS in the same period last year. The net profit margin was 9.20% and return on equity was 6.20% for EXEL. The company reported revenue of $408.79 million for the quarter, compared to $355.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.83 percent. For the current quarter, analysts expect EXEL to generate $447.51M in revenue.
Exelixis Inc.(EXEL) Company Profile
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin’s lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
